Attached files
file | filename |
---|---|
EX-99.2 - PRESS RELEASE DATED DECEMBER 2, 2016 - CEL SCI CORP | cvm_ex992.htm |
EX-23 - CONSENT OF HART AND HART LLC - CEL SCI CORP | cvm_ex23.htm |
EX-10.PPP - FORM OF SECURITIES PURCHASE AGREEMENT - CEL SCI CORP | cvm_ex10pp.htm |
EX-5 - OPINION OF HART AND HART LLC - CEL SCI CORP | cvm_ex5.htm |
EX-4.L - PLACEMENT AGENT WARRANT SERIES FF - CEL SCI CORP | cvm_ex4l.htm |
EX-4.K - FORM OF WARRANT SERIES EE - CEL SCI CORP | cvm_ex4k.htm |
EX-4.J - FORM OF WARRANT SERIES DD - CEL SCI CORP | cvm_ex4j.htm |
EX-4.I - FORM OF WARRANT SERIES CC - CEL SCI CORP | cvm_ex4i.htm |
EX-1.1 - LETTER AGREEMENT - CEL SCI CORP | cvm_ex11.htm |
8-K - CURRENT REPORT - CEL SCI CORP | cvm_8k.htm |
EXHIBIT 99.1
Contact:
Gavin de
Windt
Investor Relations
Manager
Phone: 703 506-9460
Email address:
gdewindt@cel-sci.com
|
CEL-SCI
Announces Proposed Public Offering of Common Stock and
Warrants
|
VIENNA, VA, December
1, 2016 - CEL-SCI Corporation (NYSE MKT:
CVM) ket
and other conditions shares of its common stock and warrants to
purchase common stock. The securities are to be sold by CEL-SCI
subject to market and other conditions in a public
offering.
CEL-SCI currently intends to use the net proceeds from the offering
to fund the continued development of Multikine*, LEAPS and for
other general corporate purposes.
Rodman & Renshaw, a unit of H.C. Wainwright & Co., LLC, is
acting as exclusive placement agent in connection with the
offering.
A "shelf" registration statement relating to the shares of common
stock and warrants to be issued in the proposed offering was filed
with the Securities and Exchange Commission (SEC) and was declared
effective by the SEC on October 30, 2015. This press release does
not constitute an offer to sell, or the solicitation of an offer to
buy, these securities, nor will there be any sale of these
securities in any state or other jurisdiction in which such offer,
solicitation or sale is not permitted.
A preliminary prospectus supplement and accompanying prospectus
describing the terms of the proposed offering will be filed with
the SEC. Copies of the preliminary prospectus supplement and the
accompanying prospectus relating to the securities being offered
may also be obtained from Rodman & Renshaw, a unit of H.C.
Wainwright & Co., via email at placements@hcwco.com. Electronic
copies of the preliminary prospectus supplement and accompanying
prospectus will also be available on the SEC's website at
http://www.sec.gov.
About CEL-SCI Corporation
|
CEL-SCI's work is focused on finding the best way to activate the
immune system to fight cancer and infectious diseases. Its lead
investigational immunotherapy, Multikine (Leukocyte Interleukin,
Injection), is currently being studied in a pivotal Phase 3
clinical trial as a potential neoadjuvant treatment for patients
with squamous cell carcinoma of the head and neck. Subject to the
partial clinical hold, the study was designed with the objective
that, if the study endpoint, which is an improvement in overall
survival of the subjects treated with the Multikine treatment
regimen plus the current standard of care (SOC) as compared to
subjects treated with the current SOC only, is satisfied, the study
results will be used to support applications that the Company plans
to submit to regulatory agencies in order to seek commercial
marketing approvals for Multikine in major markets around the
world. Additional clinical indications for Multikine that are being
investigated include the treatment of cervical dysplasia in HIV/HPV
co-infected women, and the treatment of peri-anal warts in HIV/HPV
co-infected men and women. A Phase 1 trial of the former indication
(treatment of cervical dysplasia in HIV/HPV co-infected women) has
been completed at the University of Maryland. The latter indication
(treatment of peri-anal warts in HIV/HPV co-infected men and women)
is being studied in a Phase 1 trial at the University of
California, San Francisco.
CEL-SCI has patents on Multikine from the US, Europe, China, and
Japan.
CEL-SCI is also developing its pre-clinical L.E.A.P.S. (Ligand
Epitope Antigen Presentation System) technology for the potential
treatment of pandemic influenza in hospitalized patients and as a
potential vaccine for the treatment of rheumatoid
arthritis.
The Company has operations in Vienna, Virginia, and in/near
Baltimore, Maryland.
Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
When used in this press release, the words "intends," "believes,"
"anticipated," "plans" and "expects," and similar expressions, are
intended to identify forward-looking statements. Such statements
are subject to risks and uncertainties that could cause actual
results to differ materially from those projected, including the
risk that the offering is subject to market and other conditions
and there can be no assurance as to whether or when the offering
may be completed or as to the actual size or terms of the offering.
Factors that could cause or contribute to such differences include,
an inability to duplicate the clinical results demonstrated in
clinical studies, timely development of any potential products that
can be shown to be safe and effective, receiving necessary
regulatory approvals, difficulties in manufacturing any of the
Company's potential products, inability to raise the necessary
capital and the risk factors set forth from time to time in
CEL-SCI's filings with the Securities and Exchange Commission,
including but not limited to its report on Form 10-K for the year
ended September 30, 2015. The Company undertakes no obligation to
publicly release the result of any revision to these
forward-looking statements which may be made to reflect the events
or circumstances after the date hereof or to reflect the occurrence
of unanticipated events.
* Multikine (Leukocyte Interleukin, Injection) is the trademark
that CEL-SCI has registered for this investigational therapy, and
this proprietary name is subject to FDA review in connection with
the Company's future anticipated regulatory submission for
approval. Multikine has not been licensed or approved for sale,
barter or exchange by the FDA or any other regulatory agency.
Similarly, its safety or efficacy has not been established for any
use. Moreover, no definitive conclusions can be drawn from the
early-phase, clinical-trials data involving the investigational
therapy Multikine. Further research is required, and early-phase
clinical trial results must be confirmed in the Phase 3 clinical
trial of this investigational therapy that is in progress and that
is currently subject to a clinical hold on enrollment of additional
new patients.